Plexus (NASDAQ:PLXS – Get Free Report) and 908 Devices (NASDAQ:MASS – Get Free Report) are both technology companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation and institutional ownership.
Analyst Ratings
This is a summary of current recommendations for Plexus and 908 Devices, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Plexus | 0 | 1 | 5 | 1 | 3.00 |
| 908 Devices | 1 | 0 | 3 | 0 | 2.50 |
Plexus currently has a consensus target price of $273.00, suggesting a potential upside of 6.92%. 908 Devices has a consensus target price of $12.83, suggesting a potential upside of 34.80%. Given 908 Devices’ higher possible upside, analysts plainly believe 908 Devices is more favorable than Plexus.
Insider and Institutional Ownership
Risk and Volatility
Plexus has a beta of 0.89, indicating that its stock price is 11% less volatile than the S&P 500. Comparatively, 908 Devices has a beta of 0.68, indicating that its stock price is 32% less volatile than the S&P 500.
Profitability
This table compares Plexus and 908 Devices’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Plexus | 4.03% | 12.46% | 5.57% |
| 908 Devices | -56.96% | -12.54% | -8.87% |
Earnings and Valuation
This table compares Plexus and 908 Devices”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Plexus | $4.03 billion | 1.69 | $172.88 million | $6.78 | 37.66 |
| 908 Devices | $56.20 million | 7.00 | $19.49 million | ($0.95) | -10.02 |
Plexus has higher revenue and earnings than 908 Devices. 908 Devices is trading at a lower price-to-earnings ratio than Plexus, indicating that it is currently the more affordable of the two stocks.
Summary
Plexus beats 908 Devices on 12 of the 15 factors compared between the two stocks.
About Plexus
Plexus Corp. provides electronic manufacturing services in the United States and internationally. It offers design, develop, supply chain, new product introduction, and manufacturing solutions, as well as sustaining services to companies in the healthcare/life sciences, industrial/commercial, aerospace/defense, and communications market sectors. The company was founded in 1979 and is headquartered in Neenah, Wisconsin.
About 908 Devices
908 Devices Inc., a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling. Its products also comprise Maven and Trace C2, an online device for bioprocess monitoring and control; and ZipChip solution, a plug-and-play, high-resolution separation platform that optimizes Mass Spec sample analysis. The company operates in the United States, Europe, the Middle East, Africa, the Asia Pacific, and rest of the Americas. 908 Devices Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Receive News & Ratings for Plexus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Plexus and related companies with MarketBeat.com's FREE daily email newsletter.
